PHILADELPHIA, PA—June 11, 2015—BioAdvance announced that during its fiscal year that will end on June 30, 2015, its life sciences portfolio companies attracted $85 million of capital from private investments and other sources.
“It’s been another strong year for our portfolio companies,” said Barbara Schilberg, CEO of BioAdvance. “While several companies have raised significant amounts of venture capital, others have received nondilutive funding, achieved product sales, secured development contracts, accessed the public markets, or progressed products through collaborations with larger companies. This progress confirms that there are multiple paths to success for life sciences companies.”
Read the Full Release Here.